Angioplasty

La Jolla Vein & Vascular Expands Services and Announces New Medical Staff

Retrieved on: 
Tuesday, April 26, 2022
Radiology, Hospitals, Health, Other Health, National Association Medical Staff Services, Family, University, GAE, Uterine fibroid, Varicose veins, Woman, Varicocele, General surgery, Pelvic congestion syndrome, Diagnosis, List, Angioplasty, Osteoarthritis, Interventional radiology, Vascular disease, Deep vein thrombosis, University of California, Moyamoya disease, Health, May–Thurner syndrome, School, USC, De Young, Medical school, Degenerative disease, Multimedia, Medical imaging, Psychology

La Jolla Vein & Vascular (LJVV), the regional leader in vein treatment, is excited to announce expanded vascular services, including endovascular procedures that rely on advanced medical imaging in real-time.

Key Points: 
  • La Jolla Vein & Vascular (LJVV), the regional leader in vein treatment, is excited to announce expanded vascular services, including endovascular procedures that rely on advanced medical imaging in real-time.
  • View the full release here: https://www.businesswire.com/news/home/20220426005279/en/
    Dr. Elliot DeYoung, Interventional Radiologist joins medical staff at La Jolla Vein & Vascular (Photo: Business Wire)
    Now spanning four locations, LJVV is better positioned to provide expert care for increasingly complex vascular conditions throughout Southern California.
  • Previously known as La Jolla Vein Care, the new LJVV name reflects the expanded service offering.
  • About La Jolla Vein & Vascular:
    La Jolla Vein & Vascular is San Diegos most comprehensive endovascular center, dedicated exclusively to the diagnosis and treatment of vascular disorders.

Global Percutaneous Transluminal Angioplasty Balloons Catheter Market Report to 2028 - Size, Share, Outlook, and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Health, Other Health, Neck, Groin, Marketing, Medtronic, Percutaneous, Angioplasty, Brain, CAGR, Region, PTA, Knee, Application, US, Cerebral arteries, Plaque, Wrist, Chameleon, Common carotid artery, Industry, Arm, Atherosclerosis, Medical imaging

The "Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type, by Material, by Application, by Diameter Size, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type, by Material, by Application, by Diameter Size, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Percutaneous transluminal angioplasty (PTA) is a procedure that opens up blocked peripheral arteries due to plaque build-up (atherosclerosis).
  • A series of x-ray images are taken to clearly view the narrowed artery after the catheter is advanced into the narrowed artery.
  • Increasing launches of angioplasty balloons catheter products in the market by key players are expected to drive the global percutaneous transluminal angioplasty balloons catheter market growth during the forecast period.

Global Laser Processing Market to Reach $21.3 Billion by 2026

Retrieved on: 
Monday, April 18, 2022
Welding, Stimulated emission, Marketing, Laser, COVID-19, Research, Medicine, Angioplasty, Coherent, Inc., CAGR, Geography, Urbanization, Light, GIA, Growth, Electromagnetic radiation, SAN, Players, Health, List of life sciences, LASER, GDP, Internet, Photon, Forecasting, Semiconductor, Intelligence, Industry, Defense, 3D printing, Radiation, Others, Architecture

SAN FRANCISCO, April 18, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Laser Processing - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, April 18, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Laser Processing - Global Market Trajectory & Analytics" .
  • Laser cutting, laser welding, hybrid laser welding, laser marking, laser drilling, laser cladding, laser brazing, and laser cleaning are among the various types of laser processes.
  • Amid the COVID-19 crisis, the global market for Laser Processing estimated at US$16.2 Billion in the year 2022, is projected to reach a revised size of US$21.3 Billion by 2026, registering a compounded annual growth rate (CAGR) of 7.3% over the analysis period.
  • China represents the largest regional market for Laser Processing, and is projected to reach US$5.3 Billion by 2026, growing at a CAGR of 9.6% over the analysis period.

Global Novel Cardiovascular Drug Delivery Devices Market (2022 to 2035) - by Type of Drug Eluted, Stent Material and Key Geographical Regions - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 14, 2022
Pharmaceutical, Health, Cardiology, Deep learning, Center, Korea Disease Control and Prevention Agency, Adoption, Degenerative disease, Artery, Stent, WHO, Restenosis, CAD, Drug-eluting stent, Incidence, Angioplasty, Stainless steel, Time Machine, CAGR, BMS, Drug combination, Patient, Metal, Death, Heart, Type, Plaque, Solution, Coronary artery disease, Safety, Cardiovascular disease, Thrombosis, CVD, Risk, Cancer, Medical device, Pharmaceutical industry, Medical imaging

The "Novel Cardiovascular Drug Delivery Devices Market, Distribution by Type of Drug Eluted, Stent Material, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Novel Cardiovascular Drug Delivery Devices Market, Distribution by Type of Drug Eluted, Stent Material, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • Cardiovascular diseases (CVD) are reported to be one of the leading causes of deaths across the globe, surpassing conditions, such as cancer and respiratory disorders.
  • According to the WHO, around one third of the annual global deaths (an estimated 18 million) can be attributed to cardiac disorders.
  • Presently, over 90 cardiovascular drug eluting stents are being offered by around 40 players located across the globe.

Alucent Biomedical Announces First Patient Enrolled in First In Human Natural Vascular Scaffolding Clinical Trial

Retrieved on: 
Tuesday, April 12, 2022
Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Prince of Wales Hospital, Doppler ultrasonography, Flinders Medical Centre, Royal Perth Hospital, Angioplasty, Peripheral artery disease, Freedom, Patient, Technology, PAD, The Alfred Hospital, Safety, Quality of life, Vascular disease, Medical device

announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology .

Key Points: 
  • announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology .
  • The first patient in the ACTIVATE II study was enrolled by Dr. Chris Delaney at Flinders Medical Centre in Adelaide.
  • Alucent Biomedical is a privately held company dedicated to developing and commercializing its breakthrough Natural Vascular Scaffolding (AlucentNVS) technology for the treatment of vascular disease.
  • Alucent Biomedical was founded by the Avera Research Institute, part of the multistate Avera Health System, in 2017.

LimFlow Raises $40 Million (€36 Million) in Series D Financing

Retrieved on: 
Tuesday, April 5, 2022
Surgery, Medical Devices, Health, Clinical Trials, Managed Care, Disease, Artery, Face, Obesity, Population, Angioplasty, Sale, Sofinnova, Leg, Mortality, Patient, Venture round, Vein, Kidney disease, Prevalence, Coronary artery disease, Quality of life, CE marking, Chronic pain, Diabetes, Chronic limb threatening ischemia, Amputation, Perfusion, Foot, Ageing, Degenerative disease, Infection, FDA, Technology, PAD, Wound healing, Peripheral artery disease, Pharmaceutical industry, Medical imaging, MD, CHRONIC LIMB-THREATENING ISCHEMIA (CLTI), LIMFLOW AND THE LIMFLOW SYSTEM

LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced it has closed a $40 million (36 million) oversubscribed Series D financing round.

Key Points: 
  • LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced it has closed a $40 million (36 million) oversubscribed Series D financing round.
  • Proceeds from the Series D financing will fund follow-up for the PROMISE II U.S. pivotal trial necessary to obtain FDA approval and will support the commercialization of the LimFlow System for deep vein arterialization.
  • The company recently completed enrollment in PROMISE II, the U.S. pivotal trial of the LimFlow System.
  • The LimFlow management team has achieved key milestones and financing needed to successfully bring the LimFlow System to market.

Global Peripheral Vascular Stents Market Analysis and Forecast Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 1, 2022
Health, Cardiology, Peripheral artery disease, Obesity, Population, Angioplasty, Forecast model, Country, Risk, Public health, CMO, Hypertension, Peripheral, Tobacco, SWOT, Prevalence, Industry, Review, Region, Diabetes, Ageing, COVID-19, Market access, Strategic planning, PAD, Patient, Disease, Pharmaceutical industry, Healthcare, Retail, Marketing

The "Peripheral Vascular Stents (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral Vascular Stents (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Peripheral Vascular Stents (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Peripheral Vascular Stents market for the year 2020 and beyond.
  • Key Inclusions of the market model are:
    Currently marketed Peripheral Vascular Stents market and evolving competitive landscape:
    Insightful review of the key industry trends.

Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud

Retrieved on: 
Friday, March 18, 2022
Cloud, Hospital, Method, Angioplasty, NEW, Smartphone, Patient satisfaction, Compliance, Sleep, History, Privacy, CEO, Manipal Hospitals, Health, MD, Technology, Google Cloud, Heart rate, Solution, AI, Founder CEO, Acquisition, Patient, Partnership, Dentistry, Medicine, Medical imaging, Fitbit

NEW DELHI and LONDON and SINGAPORE, March 18, 2022 /PRNewswire/ -- Manipal Hospitals, the second-largest healthcare services provider in India, today announced a strategic partnership with ConnectedLife built with Google Cloud to use Fitbit's wearable technology with ConnectedLife's virtual platform to monitor patient progress and empower "Continuity of Care Post-High-Risk Surgeries". Through this virtual platform, the clinical teams at Manipal Hospitals will gain a holistic view of the patient post-discharge, tailor their intervention precisely to the patient's needs, and monitor them in their journey towards a healthy post-surgery recovery.

Key Points: 
  • NEW DELHI andLONDON andSINGAPORE, March 18, 2022 /PRNewswire/ -- Manipal Hospitals, the second-largest healthcare services provider in India, today announced a strategic partnership with ConnectedLife built with Google Cloud to use Fitbit's wearable technology with ConnectedLife's virtual platform to monitor patient progress and empower "Continuity of Care Post-High-Risk Surgeries".
  • This digital initiative aims to use wearable technology to stay connected with patients post surgeries like total knee replacement, angioplasty, cardiac bypass surgery, and other high-risk surgeries.
  • "This is the beginning of a new and exciting chapter in the history of Manipal Hospitals and in the Indian healthcare eco-system.
  • "We are honoured to partner with Manipal Hospitals and Fitbit in bringing about a digital transformation within the Indian health eco-system to continuity of care post-high-risk surgeries.

LimFlow Completes Enrollment in PROMISE II U.S. Pivotal Trial of Breakthrough Device Designed to Prevent Amputations in No-Option Patients With Chronic Limb-Threatening Ischemia

Retrieved on: 
Tuesday, March 15, 2022
Biotechnology, Surgery, Medical Devices, Health, Clinical Trials, Harvard Medical School, Â, MBA, Quality of life, Mortality, Angioplasty, Technology, Face, Vein, Method, FACS, Death, Patient, Perfusion, Hospital, Coronary artery disease, FDA, Obesity, Massachusetts General Hospital, Leg, Amputation, Infection, Diabetes, Professor, Assistant, Diamond clarity, Ageing, Surgery, CE marking, Sale, Degenerative disease, Kidney disease, Wound healing, Prevalence, Foot, Incidence, Population, PAD, Chronic pain, Artery, Peripheral artery disease, Department, MS, Chronic limb threatening ischemia, Disease, Pharmaceutical industry, Medical imaging, MD, Chronic Limb-Threatening Ischemia (CLTI), LimFlow and the LimFlow System, CHRONIC LIMB-THREATENING ISCHEMIA (CLTI), LIMFLOW AND THE LIMFLOW SYSTEM

The LimFlow System is designed to reestablish arterialization in deep veins for patients who have exhausted other methods and face major amputation of their lower limbs.

Key Points: 
  • The LimFlow System is designed to reestablish arterialization in deep veins for patients who have exhausted other methods and face major amputation of their lower limbs.
  • The no-option patients treated in PROMISE II were determined by an independent physician committee to be no longer eligible for conventional endovascular or surgical therapy to treat CLTI.
  • The PROMISE II investigators are very encouraged by our experience using the LimFlow System to treat CLTI patients with no other options.
  • LimFlow also announced completion of enrollment in the CLariTI study of approximately 200 high-risk and no-option CLTI patients.

Global Peripheral Embolic Protection Devices (Cardiovascular) Market Analysis and Forecast Report, 2015-2021 & 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Health, Medical Devices, Cardiology, Region, Industry, Angioplasty, Renal artery stenosis, Plaque, EPD, Artery, Forecast model, Country, Carotid artery stenosis, Market access, Strategic planning, SWOT, COVID-19, CMO, Moyamoya disease, Pulmonary embolism, Review, Pharmaceutical industry, Weapon, Retail

The "Peripheral Embolic Protection Devices (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral Embolic Protection Devices (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • The model discusses in detail the impact of COVID-19 on Peripheral Embolic Protection Devices market for the year 2020 and beyond.
  • Currently marketed Peripheral Embolic Protection Devices market and evolving competitive landscape:
    Insightful review of the key industry trends.
  • Annualized total Peripheral Embolic Protection Devices market revenue by segment and market outlooks from 2015-2030.